Pharsight

Velcade patents expiration

VELCADE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6958319 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(1 year, 7 months ago)

US6713446 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(1 year, 7 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6713446

(Pediatric)

TAKEDA PHARMS USA Formulation of boronic acid compounds
Jul, 2022

(1 year, 1 month ago)

US6958319

(Pediatric)

TAKEDA PHARMS USA Formulation of boronic acid compounds
Jul, 2022

(1 year, 1 month ago)

Velcade is owned by Takeda Pharms Usa.

Velcade contains Bortezomib.

Velcade has a total of 4 drug patents out of which 4 drug patents have expired.

Expired drug patents of Velcade are:

  • US6713446*PED
  • US6958319*PED
  • US6958319
  • US6713446

Velcade was authorised for market use on 13 May, 2003.

Velcade is available in injectable;intravenous, subcutaneous dosage forms.

The generics of Velcade are possible to be released after 25 July, 2022.

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity (PED) Apr 8, 2022

Drugs and Companies using BORTEZOMIB ingredient

Market Authorisation Date: 13 May, 2003

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

How can I launch a generic of VELCADE before it's drug patent expiration?
More Information on Dosage

VELCADE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic